Watch replays of the main stage programming from the SOSV Climate Tech Summit (Nov. 5-6)

Karma Biotechnologies

LNP technology that can deliver both DNA and RNA payloads to solid tumor microenvironments

Team

Andrew Gray

Past-CEO & Co-Founder / CEO & Co-Founder

Joseph Turner

President, CFO, and CBO

Alan Johnson

COO & Co-founder

Company details

Karma Biotech is an oncology company targeting solid tumors, starting with colorectal cancer. Their technology aims to deliver cytokines and other biologicals, such as IL-15, specifically to tumor and metastatic sites, avoiding the dangers of systemic toxicity. This localized IL-15 will turn cold tumors hot, allowing the body to clear the cancer. 

The founders at Karma rationally designed super stable LNPs that are effective at delivering both DNA and/or RNA without electroporation. Their proprietary LNPs efficiently transfect macrophages in the spleen – which then home to tumor sites and produce the payload (e.g., IL-15) at the tumor microenvironment. This is one of the most elegant methods we’ve seen at fighting hard-to-penetrate solid tumors. While they’re quickly advancing through their own internal drug program, they can also generate some early revenue by partnering out with other pharma companies who have already been impressed by Karma’s latest data package (summer 2023).

Get In Touch with Karma Biotechnologies

Please tell us a little bit about yourself and why you'd like to get connected. Karma Biotechnologies + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.